PrescriptionDrugs.org

What to Expect When Starting Empagliflozin

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Empagliflozin (brand name Jardiance) is an SGLT2 inhibitor prescribed for type 2 diabetes and, increasingly, for heart failure and chronic kidney disease — even in people without diabetes. It works by preventing your kidneys from reabsorbing glucose back into your blood, causing excess sugar to be excreted in your urine.

This mechanism of action — literally peeing out sugar — leads to some unique and predictable effects, including increased urination, modest weight loss, and an increased risk of genital yeast infections. Understanding these effects in advance helps you prepare and manage them effectively.

Empagliflozin has demonstrated remarkable cardiovascular and kidney-protective benefits in major clinical trials (EMPA-REG OUTCOME, EMPEROR trials). These benefits go beyond blood sugar control, which is why it is increasingly prescribed for heart and kidney conditions.

Week-by-week timeline

Days 1-3Increased urination is the medication working as intended — it is removing excess glucose from your blood through your urine. Stay well hydrated. This is most noticeable in the first few days.

Noticeable Urination Changes

The most immediate effect of empagliflozin is increased urination as your kidneys begin excreting excess glucose. You may also notice that your urine looks or smells different.

  • Increased frequency of urination
  • Larger volume of urine
  • Urine may have a sweet smell (due to glucose content)
  • Mild thirst
  • Possible mild dizziness from fluid loss
Week 1-2If you are also taking insulin or sulfonylureas, the added blood-sugar-lowering effect of empagliflozin may increase your risk of hypoglycemia (low blood sugar). Your doctor may adjust your other diabetes medications.

Blood Sugar and Weight Effects

Blood sugar levels are decreasing as glucose is excreted rather than reabsorbed. You may notice modest weight loss from a combination of calorie loss (glucose in urine) and fluid loss.

  • Blood sugar readings improving
  • Possible weight loss of 2-4 pounds (mostly water weight initially)
  • Urination frequency stabilizing somewhat
  • Increased thirst that requires conscious hydration
  • Possible mild drop in blood pressure
Weeks 2-4Genital yeast infections affect about 5-10% of women and 3-5% of men on SGLT2 inhibitors. Maintaining good genital hygiene and staying hydrated can help reduce this risk. Treat promptly if symptoms develop.

Infection Risk Window

The increased glucose in your urine creates an environment favorable for yeast growth. Genital yeast infections (mycotic infections) are one of the most common side effects of SGLT2 inhibitors.

  • Blood sugar consistently improved
  • Weight loss continuing at a modest pace
  • Possible genital itching or discomfort (early sign of yeast infection)
  • Possible urinary tract infection symptoms
  • Body adjusting to the medication
Months 1-3The cardiovascular and kidney benefits of empagliflozin have been demonstrated to emerge relatively early (within months) in clinical trials and continue to accumulate over years.

Metabolic Benefits Establishing

Beyond blood sugar control, empagliflozin is beginning to provide cardiovascular and kidney-protective effects. HbA1c (a 3-month average blood sugar marker) will show the full impact at 3 months.

  • HbA1c reduction typically 0.5-0.8% at 3 months
  • Sustained modest weight loss (4-6 pounds average)
  • Possible mild blood pressure reduction
  • Reduced cardiovascular risk building
  • Kidney function protection ongoing
Months 3+Long-term use of empagliflozin is well-supported by clinical evidence. The cardiovascular mortality benefit demonstrated in the EMPA-REG OUTCOME trial was significant — a 38% relative risk reduction in cardiovascular death.

Long-Term Cardiorenal Protection

Empagliflozin provides ongoing blood sugar control, weight management, and importantly, cardiovascular and kidney protection with continued use.

  • Stable blood sugar control
  • Maintained weight loss
  • Cardiovascular risk reduction
  • Kidney function protection
  • Periodic monitoring of kidney function and HbA1c

When to call your doctor

Contact your healthcare provider if you experience:

  • Signs of diabetic ketoacidosis (DKA): nausea, vomiting, abdominal pain, excessive tiredness, difficulty breathing — DKA can occur even with normal blood sugar on SGLT2 inhibitors
  • Genital pain, redness, swelling, or foul-smelling discharge (possible necrotizing fasciitis of the perineum — Fournier gangrene — extremely rare but life-threatening)
  • Signs of severe urinary tract infection: fever, back pain, blood in urine, painful urination
  • Signs of severe dehydration: extreme thirst, very dry mouth, dizziness, confusion, significantly decreased urination
  • Symptoms of low blood sugar if on insulin or sulfonylureas: shakiness, sweating, confusion, rapid heartbeat
  • Signs of allergic reaction: rash, hives, swelling, difficulty breathing
  • Significant unexplained weight loss beyond expected

Tips for getting started

Take empagliflozin once daily in the morning, with or without food. Morning dosing is preferred so that the increased urination occurs mostly during daytime hours rather than disrupting sleep.

Stay well hydrated — drink plenty of water throughout the day. The medication works by excreting glucose through urine, which requires adequate fluid intake. Dehydration can lead to dizziness, low blood pressure, and kidney problems. Be especially careful in hot weather and during exercise.

Practice good genital hygiene to reduce the risk of yeast infections. Wear breathable cotton underwear, keep the genital area clean and dry, and treat any yeast infection symptoms promptly with over-the-counter antifungal treatments or by contacting your doctor. Be aware of the rare but serious risk of diabetic ketoacidosis (DKA) — this can occur even with normal blood sugar levels on SGLT2 inhibitors. If you feel sick with nausea, vomiting, and fatigue, check for ketones if possible and seek medical attention.

Frequently asked questions

More about Empagliflozin

Empagliflozin drug guideSide effects, dosage, interactions, and moreSemaglutide (Ozempic) vs EmpagliflozinCompare these medicationsEmpagliflozin vs DapagliflozinCompare these medicationsDapagliflozin vs EmpagliflozinCompare these medicationsMetformin & EmpagliflozinInteraction detailsEmpagliflozin & Insulin glargineInteraction details

References

  1. [Observational] Empagliflozin Drug Label https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fad80e47-834e-4e83-b3c9-0c3e11b9e15e Accessed 2026-03-01.
  2. [Observational] Empagliflozin Monograph https://medlineplus.gov/druginfo/meds/a614045.html Accessed 2026-03-01.
  3. [Observational] EMPA-REG OUTCOME Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1515920 Accessed 2026-03-01.
  4. [Observational] SGLT2 Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Accessed 2026-03-01.
  5. [Observational] ADA Standards of Care in Diabetes https://diabetesjournals.org/care/issue/47/Supplement_1 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: